Sequence analysis of PSORS1 candidate genes
High-resolution haplotypic refinement of the PSORS1 psoriasis susceptibility locus
The development of psoriasiform dermatitis depends on CD18 deficiency of CD4+ CD25+ regulatory T cells in a murine psoriasis model
Placental growth factor (PlGF) and vascular endothelial growth factor (VEGF) in inflammatory skin disease
A pharmacogenetic study of methotrexate and polymorphisms of folate and pyrimidine metabolism in psoriasis
Identification of molecular and cellular pathways of autoimmune inflammation through pharmacogenomic study of ciclosporin in psoriasis
Identification and characterization of a novel, psoriasis-susceptibility-related, noncoding RNA gene, PRINS
Differential expression of antibiotic peptides in psoriasis and eczema
Protein expression of TNF-a in psoriatic skin is regulated at a post-transcriptional level by MK2
Disease-specific alleles of the MHC class I related gene, MICA, are associated with type I psoriasis and psoriatic arthritis
Complex nature of genetic association of psoriasis vulgaris and psoriatic arthritis with SLC12A8 at PSORS5
T-cell clones in psoriatic skin lesions and streptococcal angina share common TCR rearrangements
Immunological evidence for increased reactivity to secreted Streptococcus pyogenes proteins in chronic plaque psoriasis
Psoriatic CD4+ CD25) effector T cells hyperproliferate in vitro, possess a low activation threshold and are aberrant in their cytokine production
What clinical trials teach us about the biology of psoriasis
Interleukin-20 in human skin organ culture is synthesized by keratinocytes and transferred to epidermal dendritic cells
An essential functional role for epidermal T cells in the development of psoriasis
Amphiregulin mediates the psoriatic phenotype and induces a T-cell-restricted skin response
T cells, immunosurveillance and skin disease
Treatment of moderate-to-severe psoriasis with oral dimethyl fumarate (BG00012)
The anti-TNF-α monoclonal antibody, infliximab, effects cellular proliferation and inflammation in psoriatic lesions
Previous biological therapies influence the rate of response to etanercept in chronic plaque psoriasis
Tumour necrosis factor (TNF) inhibition rapidly downregulates multiple pro-inflammatory pathways in psoriasis plaques
Appraising the clinical and cost effectiveness of therapies for inflammatory disease
Role of polymorphic transcription factors in autoimmunity
Alefacept induces late-onset apoptosis in infiltrating dermal cells in psoriatic plaques from clinically responsive patients
Mitogen- and stress-activated protein kinase 1 is a potential target in the treatment of psoriasis
Systemic therapy for psoriasis
Polymorphisms of corticotropin-releasing hormone in psoriasis vulgaris
High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis
Corticotropin-releasing hormone (CRH), CRH receptor (CRH-R) and NURR1 are increased in psoriasis, further evidence of a brain-skin axis?
The CX3CL1-CX3CR1 system and psoriasis
Gene expression profiles of serum-induced abnormal keratinocyte differentiation and regulation of B7-H1 by IFN-γ
HLA-Cw*0602 is associated with a two-fold higher prevalence of streptococcal throat infection at the onset of both guttate and plaque psoriasis
Value of isolated populations in probing for genes in psoriatic arthritis and psoriasis
Characterizing susceptibility to phenotypic variations of psoriasis by comparing allelic association signals on chromosome 6
Modulation of the expression of antimicrobial peptides
Interleukin 20 controls psoriasis induction and maintenance
Interleukin-20 protein and related receptors in psoriatic skin plaques
IL-22 regulates the expression of genes responsible for antimicrobial defence, cellular differentiation, and mobility in keratinocytes
IL-19, IL-20, and IL-24
In vitro and in situ expression of IL-23 by keratinocytes
Exogenous IL-1β modulates tight junction claudin expression in vitro
Correlation of autoimmune phenomena and psoriasis vulgaris
CD4+CD45RO+CLA+CCR4+CCR10+ T cells obtained from chronic plaque psoriasis (CPP) patients activate autologous mononuclear cells to secrete elevated TNF-a and IL-1β during cell-cell contact
The expression of HLA-C is reduced in psoriatic skin compared with healthy skin and eczema
The TLR3-mediated pro-inflammatory response in human keratinocytes is augmented by IFN-a sensitization
Myeloid (CD11c+) dendritic cells are a new inflammatory cell type highly correlated with psoriasis disease activity
The association of psoriasis with killer cell immunoglobulin-like receptor in the Korean population and the influence of age of onset
Early psoriatic lesions show a lower lymphatic vessel density but a similar blood vessel density compared with established plaques
Neuropeptides in psoriasis
Comparison of calcipotriol 005% (Daivonex) ointment and tazarotene 1% (Zorac) gel in the treatment of plaque psoriasis; a pilot study
Narrowband UVB decreases mast cell density and downregulates IL-8 expression in psoriatic lesions
A long-term evaluation of erythema and pigmentation induced by different wavelengths of ultraviolet radiation
Quantification of erythema induced by TL-01 MED testing
A comparative study on the effects of treatment with 585-nm pulsed dye laser (PDL) and with UVB-TL-01 in plaque-type psoriasis
Action mechanism of photochemotherapy (PUVA) in patients with psoriasis
Efficacy and safety of switch from high- to low-dose topical tacalcitol in combination with bath-PUVA therapy in patients with psoriasis vulgaris
Ultraviolet light-sparing effect of acitretin in bath PUVA therapy of psoriasis is differentially related to skin types
Fumaric-acid esters (Fumaderm®) for severe, treatment resistant psoriasis
Evaluation of possible immune mediators causing flushing after BG00012 (dimethyl fumarate) administration in patients with psoriasis
Dimethyl fumarate blocks T-cell adhesion to selectins in vitro
Therapeutic efficacy of soft X-ray therapy in a severe form of nail psoriasis
Effect of naphthalene therapy on proliferative activity, CD4 and CD8 cell count, apoptosis and angiogenesis in the skin of patients with psoriasis
Initial experience with routine administration of biologicals in psoriasis
Alefacept rapidly activates gene expression in T-cells, and therapeutic responders show a unique pattern of gene activation
Efalizumab therapy and incidence of arthropathy adverse events
Safety and tolerability of efalizumab therapy
Development of localized papular eruptions during treatment with efalizumab in psoriasis
Treatment of erythrodermic psoriasis with etanercept
A review of etanercept in 44 patients with recalcitrant psoriasis
Etanercept and quality of life in patients with psoriasis
Reduced T-cell monitoring schedules for patients treated with alefacept
In situ effects of etanercept therapy in psoriatic lesional skin
Severe psoriasis with chronic active hepatitis C
Infliximab for severe, treatment resistant psoriasis
A phase II study of STA-5326, an oral IL-12 and IL-23 inhibitor, in patients with moderate-to-severe chronic plaque psoriasis (CPP)
Preliminary histological and gene expression results
Preliminary clinical safety and efficacy results from an open-label phase II study of STA-5326, an oral IL-12/IL-23 inhibitor, in patients with moderate-to-severe chronic plaque psoriasis
Human anti-interleukin IL-12/IL-23 p40 mAb (CNTO1275) inhibits IL-12-induced expression of skin homing molecule, cutaneous lymphocyte antigen and IL-12 receptors on activated peripheral blood T lymphocytes
Blockade of VLA-2, (alpha2beta1 integrin) inhibits psoriasis in a T-cell-independent manner
Clearance of lifelong pustular psoriasis with recombinant soluble tumour necrosis alpha receptor (etanercept) treatment
Pharmacological evaluation of a new potent p38 MAP kinase inhibitor as a systemic drug for psoriasis
High-dose initiation of etanercept in plaque psoriasis and psoriatic arthritis
Psoriasis therapeutics
Patients with psoriatic arthritis have an increased number of lymphocytes in the duodenal mucosa in comparison with patients with psoriasis vulgaris
Patients with psoriasis and psoriatic arthritis have increased rates of serological markers for gluten sensitivity and coeliac sprue
Reverse transcriptase activity in psoriatic lesions
Regulation of keratinocyte proliferation by the p63-IKKalpha pathway in psoriasis
Lithium inhibits the activation of the keratinocyte transglutaminase promoter through a GSK-3β-independent pathway
The prevalence of psoriasis in patients with alcoholic liver disease
Diseases associated with psoriasis
Co-medication in patients with severe psoriasis
Severe and long-standing psoriasis is associated with an increased prevalence and severity of coronary artery calcification
Expression of the cleavable precursor peptide of desmocollin 3 in plaque psoriasis
The coexistence of psoriasis and dermatomyositis; a rare association with therapeutic problems
Comorbidity of anxiety disorders and sleep problems in patients with psoriasis
Comorbidity of depressive disorders, substance abuse, and suicidality in patients with psoriasis
Quality of life in patients with psoriasis
Improvement in quality of life in psoriasis is correlated with the improvement in psoriasis area and severity index following phototherapy
Clinical classification of psoriasis vulgaris on the basis of the lesion size
Altered expression of prohibitin in psoriatic lesion compared with uninvolved skin
The homocysteine status of patients with psoriasis and its relationship to disease severity
The memory of parental models and the affective motivational axis in patients diagnosed with psoriasis
The epidemiological investigation of pruritic patients with psoriasis and the study of pruritogenic factors using confocal laser scanning microscopy
Efficacy and safety of adalimumab in psoriasis and psoriatic arthritis
Infliximab therapy in plaque-type and arthropathic psoriasis
Fas mediates lymphocyte induction of psoriasis